The clinical pharmacology of etoposide: An update

Cancer Treatment Reviews

Volumn 22, Issue 3, 1996, Pages 179-221

  Joel, Simon ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; APHIDICOLIN; ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOSPORIN; CYTARABINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOFOS; ETOPOSIDE; GLYCOPROTEIN P; IFOSFAMIDE; INTERLEUKIN 1; IRINOTECAN; METHOTREXATE; PACLITAXEL; RETINOIC ACID; TAMOXIFEN; TENIPOSIDE; TOPOTECAN; TUMOR NECROSIS FACTOR; VALSPODAR; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COMPLEX FORMATION; DNA CLEAVAGE; DNA DAMAGE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; GENE MUTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; REVIEW;

EID: 0029780802     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90002-X     Document Type: Article

References (317)

1. Roca, J. (1995) The mechanisms of DNA topoisomerases. TIBS 20: 156-160.
2. Berger, J., Gamblin, S., Harrison, S. et al. (1996) Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232.
3. Froelich-Ammon, S. & Osheroff, N. (1995) Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270: 21429-21432.
4. Pommier, Y, Leteurtre, R, Fesen, M. R. et al. (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542.
5. Pommier, Y. (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol. 32: 103-108.
6. Burden, D. A., Goldsmith, L. J. & Sullivan, D. M. (1993) Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II. Biochem. J. 293: 297-304.
7. Gasser, S. M., Walter, R., Dang, Q. et al. (1992) Topoisomerase II: its functions and phosphorylation. Antonie Van Leeuwenhoek 62: 15-24.
8. Cardenas, M. E. & Gasser, S. M. (1993) Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. J. Cell. Sci. 104: 219-225.
9. Fry, A. M. & Hickson, I. D. (1993) Phosphorylation modulates the enzymatic activity of human topoisomerase II alpha protein. Proc. Annu. Meet. Am. Assoc. Cancer Res. 34.
10. DeVore, R. F., Corbett, A. H. & Osheroff, N. (1992) Phosphorylation of topoisomerase li by casein kinase li and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino) methane-sulfon-M-Anisidide. Cancer Res. 52: 2156-2161.
11. Spitzner, J. & Muller, M. (1988) A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 16: 5533-5556.
12. Udvardy A. & Schedl, P. (1991) Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo. Mol. Cell. Biol. 11: 4973-4984.
13. Pommier, Y, Capranico, G., Orr, A. et al. (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide [published erratum appears in Nucleic Acids Res. 1991 19: 7003]. Nucleic Acids Res. 19: 5973-5980.
14. Corbett, A. H. & Osheroff, N. (1993) When good enzymes go bad: conversion of topoisomerase Il to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 6: 585-597.
15. Ferguson, L. R. & Baguley, B. C. (1994) Topoisomerase II enzymes and mutagenicity. Environ. Mol. Mutagen. 24: 245-261.
16. Beck, W.T., Kime, R. & Chen, M. (1994) Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Cancer Chem. Pharmacol. 34: S14-18.
17. Berger, N. A., Chatterjee, S., Schmotzer, J. A. et al. (1991) Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc. Nat. Acad. Sci. USA 88: 8740-8743.
18. Wang, L. M. & Capizzi, R. L. (1990) Pharmacologic synergy between ARA-C and inhibitors of topoisomerase II (Topo II). Proc. Am. Assoc. Cancer Res. 31: 437.
19. Joel, S. P. & Slevin, M. L. (1994) Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chem. Pharacol. 34: S84-88.
20. Juliano R. & Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Acta. 455.
21. Endicott, J. & Ling, V. (1989) The biochemistry of p-glycoprotein mediated multidrug resistance. Ann. Rev. Biochem. 58: 137-171.
22. Chan, H. S., DeBoer, G., Thorner, P. S. et al. (1994) Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol. Oncol. Clin. North Am. 8: 383-410.
23. Patel, N. & Rothenberg, M. (1994) Multidrug resistance in cancer chemotherapy. Invest. New Drugs 12: 1-13.
24. Childs, S. & Ling, V. (1994) The MDR superfamily of genes and its biological implications. Important Adv. Oncol.
25. Mickisch, G. H., Pai, L. H., Gottesman, M. M. et al. (1992) Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice. Cancer Res 52: 4427-4432.
26. Sonneveld P., Marie, J. P., Lokhorst, H. M. et al. (1994) Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporin and SDZ PSC 833. Anticancer Drugs 5.
27. Lum B. L., Gosland, M. P., Kaubisch, S. et al. (1993) Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13: 88-109.
28. Lum B. L., Kaubisch, S., Yahanda A. M. et al. (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642.
29. Lum, B. L., Fisher, G. A., Brophy N. A. et al. (1993) Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72: 3502-3514.
30. McLeod, H. (1994) Clinical reversal of the multidrug resistance phenotype: True tumour modulation of pharmacokinetic interaction? Eur. J. Cancer 30A: 2039-2041.
31. Erlichman, C., Moore, M., Thiessen, J. et al. (1994) A phase I trial of doxorubicin (D) and PSC833: a modulator of multidrug resistance (MDR). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
32. Sonneveld, P., Marie, J. P., Laburte, C. et al. (1994) Phase I study of SDZ PSC833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35.
33. Wilson, W. H., Jamis-Dow, C., Bryant, G. et al. (1995) Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol. 13: 1985-1994.
34. Cowie, F. J., Pinkerton, C. R., Phillips, M. et al. (1995) Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877-881.
35. Smith, D. C. & Trump, D. L. (1995) A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother Pharmacol 36: 65-68.
36. Millward MJ, Lien EA, Robinson A. et al. (1994) High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 51: 79-83.
37. Kaye, S. (1993) P-glycoprotein (P-gp) and drug resistance-time for reappraisal. Br. J. Cancer 67: 641-643.
38. Thomas, G. A., Barrand, M. A., Stewart, S. et al. (1994) Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer 11: 1705-1709.
39. Doyle, L. A., Ross, D. D., Ordonez, J. V. et al. (1994) An etoposide-resistant small cell lung cancer subline overexpresses the MRP gene. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35.
40. Beck, J., Handgretinger R., Dopfer, R. et al. (1995) Expression of MDR1, MRP, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br. J. Haematol. 89: 356-363.
41. Friche, E., Nissen, N. I. & Beck, W. T. (1995) MRP gene expression in heavily chemotherapy treated AML patients. Proc. Annu. Am. Assoc. Cancer Res. 36.
42. Twentyman, PR. (1992) MDR1 (P-glycoprotein) gene expression-implications for resistance modifier trials. J. Natl. Cancer Inst. 84: 1458-1460.
43. Beck, W., Danks, M., Wolverton, J. et al. (1994) Resistance of mammalian tumour cells to inhibitors of DNA topoisomerase II. Advances in Pharm. 29B: 145-169.
44. Doyle, L. (1994) Topoisomerase Il expression in cancer cell lines and clinical samples. Cancer. Chemo. Pharm. 34 (Suppl.): S32-S40.
45. Kasahara, K., Fujiwara, Y, Sugimoto, Y. et al. (1992) Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J. Nat. Cancer Inst. 84: 113-118.
46. Doyle, L. A., Kaufmann, S. H., Long, B. H. et al (1991) Evaluation of topoisomerase II expression in relation to sensitivity to etoposide in small-cell lung cancer (Sclc) Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10.
47. Doyle, L., Qin, J., Ross, D. et al. (1992) Expression of topoisomerase II in human leukaemia cells. Proc. Am. Assoc. Cancer Res. 33: 237.
48. Kaufmann SH, Karp, J. E., Jones, R. J. et al. (1994) Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83: 517-530.
49. Bigioni, M., Capranico, G. & Zunino, F. (1994) Base mismatch and mutation analyses of topoisomerase II DNA cleavage. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35.
50. Nitiss, J. L., Vilalta, P. M., Wu, H. et al. (1994) Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol. Pharmacol 46: 773-777.
51. Chen, M. & Beck, W. T. (1993) Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 53: 5946-5953.
52. Chan, V. T., Ng, S. W., Eder, J. P. et al. (1993) Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem. 268: 2160-2165.
53. Danks, M. K., Warmoth, M. R., Friche, E. et al. (1993) Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 53: 1373-1379.
54. Danks, M. K., Beck, W. T. & Suttle, DP. (1993) Topoisomerase II alpha mutation in leukemic cells from a patient with lineage switch AML. Proc. Annu. Am. Assoc. Cancer Res. 24.
55. Gudkov, A. V., Zelnick, C., Kazarov, A. R. et al. (1992) Genetic elements suppressing human topoisomerase II and inducing resistance to topoisomerase Ii poisons. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33.
56. Takano, H., Kohno, K., Ono M. et al. (1991) Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 51: 3951-3957.
57. Ritke, M. K., Allan, W. P., Fattman, C. et al. (1994) Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol. Pharmacol. 46: 58-66.
58. Hashimoto, H., Chatterjee, S. & Berger, N. (1995) Inhibition of etoposide induced DNA recombination and mutant frequency by bcl-2 protein overexpression. Cancer Res. 55: 4029-4035.
59. Kamesaki, S., Kamesaki, H., Jorgensen, T. J. et al. (1993) bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced Dna strand breaks and their repair [published erratum appears in Cancer Res 1994; 54: 3074]. Cancer Res. 53: 4251-4256.
60. Fan, S, el-Deiry W. S., Bae, I. et al. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to Dna damaging agents. Cancer Res. 54: 5824-5830.
61. Clarke, A. R., Purdie, C. A., Harrison, D. J. et al. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852.
62. Negri, C., Bernardi, R., Braghetti, A. et al. (1993) The effect of the chemotherapeutic drug VP-16 on poly(ADP-ribosylation) in apoptotic HeLa cells. Carcinogenesis 14: 2559-2564.
63. Whitacre, C. M., Chatterjee, S. & Berger, N. A. (1994) Potential involvement of poly(ADP-ribose) polymerase in regulation of p53 levels and subsequent apoptosis by etoposide. Proc. Annu. Meet. Am. Assoc. Cancer Res. 35.
64. Chatterjee, S., Cheng, M. F., Berger, R. B. et al. (1995) Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Res. 55: 868-873.
65. Pederson-Bjergaard J. & Larsen, S. (1982) Incidence of acute nonlymphocytic leukaemia, preleukaemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N. Engl. J. Med. 307: 965-971.
66. Pederson-Bjergaard J. (1985) Incidence, previous treatment and chromosome characteristics of secondary acute non-lymphocytic leukemia. Cancer Treat. Rev. 12: 65-75.
67. Ratain, M. J., Kaminer, L. S., Bitran, J. D. et al. (1987) Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 70: 1412-1417.
68. Pui, C. H., Behm, F. G., Raimondi, S. C. et al. (1989) Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med. 321: 136-142.
69. Pui, C. H., Ribeiro, R. C., Hancock, M. L. et al (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 325: 1682-1687.
70. Pui, C-H., Relling, M., Rivera, G. et al. (1995) Epipodophyllotoxin-related acute myeloid leukaemia: a study of 35 cases. Leukaemia 9: 1990-1996.
71. Boshoff, C., Begent, R. H., Oliver, R. T. et at. (1995) Secondary tumours following etoposide containing therapy for germ cell cancer. Ann. Oncol. 6: 35-40.
72. Pedersen-Bjergaard, J., Daugaard, G., Hansen, S. W. et al. (1991) Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338: 359-63.
73. Bajorin, D. F., Motzer, R. J., Rodriguez, E. et al. (1993) Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J. Natl. Cancer Inst. 85: 60-62.
74. Nichols, C. R., Breeden, E. S., Loehrer, P. J. et al. (1993) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. Natl. Cancer Inst. 85: 36-40.
75. Bokemyer, C. & Schmoll, H. J. (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol. 11: 1703-1709.
76. Sandoval, C., Pui, C. H., Bowman, L. C. et al. (1993) Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J. Clin. Oncol. 11: 1039-1045.
77. Kreissman, S., Gelber, R., Cohen, H. et al. (1992) Incidence of secondary acute myelogenous leukaemia after treatment of childhood acute lymphoblastic leukaemia. Cancer 70: 2208-2213.
78. Lorico, A, Rappa, G., Boiocchi, M. et al. (1988) Increase in etoposide-induced topoisomerase II-mediated DNA breaks after cell synchronization induced by low doses of methotrexate. Biochem. Pharmacol. 37: 1883-1884.
79. Pui, C. H., Relling, M. V., Behm, F. G. et al. (1995) L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9: 1680-1684.
80. Haupt, R, Fears, T. R., Rosso, P. et al. (1994) Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis. Ped. Hematol. Oncol. 11: 499-507.
81. Farhi, D. C., Odell, C. A. & Shurin, S. B. (1993) Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood. Am. J. Clin. Pathol. 100: 270-275.
82. Smith, M. R., Rubinstein, L., Cazenave, L. et al. (1993) Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J. Nat. Cancer Inst. 85: 554-558.
83. Maraschin, J., Dutrillaux, B. & Aurias, A. (1990) Chromosome aberrations induced by etoposide (VP-16) are not random. Int. J. Cancer 46: 808-812.
84. Mamuris, Z., Prieur, M., Dutrillaux, B. et al. (1989) The chemotherapeutic drug melphalan induces breakage of chromosome regions rearranged in secondary leukaemia. Cancer Genet. Cytogenetic 37: 65-71.
85. Pedersen-Bjergaard J. & Rowley, J. D. (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83: 2780-2786.
86. Cimino, G., Moir, D., Canaani, O. et al. (1991) Cloning of ALL-1, the locus involved in leukaemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res. 51: 6712-.
87. Chen, C. S., Sorenson, P. H., Domer, P. H. et al. (1993) Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81: 2386-2393.
88. Gu, Y, Nakamura, T., Alder, H. et al. (1992) The t(4; 11) chromosome translocation of human acute leukemias fuses the ALL-1 gene related to Drosophila trithorax, to the AF-4 gene. Cell 71: 701-708.
89. Gu, Y, Cimino, G., Alder, H. et al. (1992) The (4; 11)(q21; q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc. Natl. Acad. Sci. USA 89: 10464-10468.
90. Gu, Y, Alder, H, Nakamura, T. et al. (1994) Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res. 54: 2326-2330.
91. Negrini, M., Felix, C. A., Martin, C. et al. (1993) Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9; 11) chromosome translocation in acute myeloid leukemia. Cancer Res. 53: 4489-4492.
92. Domer, P. H., Fakharzadeh S. S., Chen, C. S. et al. (1993) Acute mixed-lineage leukemia t(4; 11)(q21; q23) generates an MLL-AF4fusion product. Proc. Natl. Acad. Sci. USA 90: 7884-7888.
93. Domer, P. H., Head, D. R., Renganathan, N. et al. (1995) Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia 9: 1305-1312.
94. Super, H. J., McCabe N. R., Thirman, M. J. et al. (1993) Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82: 3705-3711.
95. Hunger, S. P., Tkachuk, D. C., Amylon, M. D. et al. (1993) HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood 81: 3197-3203.
96. Felix, C. A., Lange, B. J., Hosler, M. R. et al. (1995) Chromosome band 11q23 translocation breakpoints are DNA topoisomerase Il cleavage sites. Cancer Res. 55: 4287-4292.
97. Pommier, Y, Capranico, G. & Kohn, K. W. (1988) Local DNA sequence requirements for topoisomerase II-induced DNA cleavage produced by amsacrine and teniposide. Proc. Annu. Meet. Am. Assoc. Cancer Res. 32.
98. Han, Y H., Austin, M. J., Pommier, Y et al. (1993) Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro. J. Mol. Biol. 229: 52-66.
99. Broeker P, Super, H., Thirman M. et al. (1996) Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukaemia and in treatment-related acute myeloid leukaemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87: 1912-1922.
100. Li, L. & Bray, P. F. (1993) Homologous recombination among the three intragene Alu sequences causes and inversion-deletion resulting in the hereditary bleeding disorder Glanzmann thrombasthenia. Am J Hum Genet 53: 140-149.
101. Kas, E. & Laemmli, U. (1992) In vivo topoisomerase II cleavage of the Drosophils histone and setellite III repeats: DNA sequence and structural characteristics. EMBO 11: 705-716.
102. Clark, P. I. & Slevin, M. L. (1987) The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinetics 12: 223-52.
103. Clark, P. I. (1992) Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin. Oncol. 19: 20-7.
104. Hande, K. R. (1992) Etoposide pharmacology. Semin. Oncol. 19: 3-9.
105. Stewart, C. F. (1994) Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother. Pharmacol. 34.
106. van Maanen JM, de Vries J, Pappie D. et al. (1987) Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res. 47: 4658-4662.
107. van Maanen J. M., Verkerk, U. H., Broersen, J. et al. (1988) Semi-quinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free Rad. Res. Comm. 4: 371-384.
108. D'Incalci, M., Rossi, C., Zucchetti, M. et al. (1986) Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res. 46: 2566-2571.
109. Relling, M. V., Evans, R., Dass, C. et al. (1992) Human cytochrome P450 metabolism of teniposide and etoposide. J. Pharmacol. Exp. Therap. 261: 491-496.
110. Relling, M. V., McLeod, H. L., Bowman, L. C. et al. (1994) Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther. 56: 503-11.
111. van Maanen, J. M., Retel, J., de Vries, J. et al (1988) Mechanism of action of antitumor drug etoposide: a review. J. Nat. Cancer Inst. 80: 1526-1533.
112. Creaven, P. J. (1984) The clinical pharmacology of etoposide (VP-16) in adults. In: Issell, B. F., Mauggia, F. M. & Carter, S. K., eds, Etoposide (VPT6): Current Status and New Developments. London: Academic Press, pp. 103-114.
113. Joel, S. P., Hall, M., Gaver, R. C. et al. (1995) Complete recovery of radioactivity after administration of 14C-etoposide in man (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin Oncol. 14.
114. Holthuis, J. J., Postmus, P. E., Van O. W. et al. (1986) Pharmacokinetics of high dose etoposide (VP 16-213). Eur. J. Cancer Clin. Oncol. 22: 1149-1155.
115. Sinkule, J. A. (1984) Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 4: 61-73.
116. Ho, D., Kanellopoulos, K., Yap, H., et al. (1983) Clinical pharmacology of etoposide by radioimmunoassay. Proc. Am. Assoc. Cancer Res. 24: 131.
117. D'Incalci M, Sessa, C., Rossi, C. et al. (1985) Pharmacokinetics of etoposide in gestochoriocarcinoma. Cancer Treat. Rep. 69: 69-72.
118. Hande, K., Anthony, L., Hamilton, R. et al. (1988) Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Cancer Res. 48: 1829-1834.
119. Hande, K. R., Wolff, S. N., Greco, F. A. et al. (1990) Etoposide kinetics in patients with obstructive jaundice. J. Clin Oncol 8: 1101-1107.
120. Stewart, C. F., Pieper, J. A., Arbuck, S. G. et al. (1989) Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Therap. 45: 49-55.
121. Stewart, C. F., Arbuck, S. G., Fleming, R. A. et al. (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther. 50: 385-393.
122. Joel, S, Shah, R., Clark, P. et al. (1996) Predicting etoposide toxicity: Relationship to organ function and protein binding. J. Clin. Oncol. 14: 257-267.
123. Stewart, C. F., Arbuck, S. G., Fleming, R. A. et al. (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J. Clin. Oncol. 8: 1874-1879.
124. Ratain, M. J., Mick, R., Schilsky, R. L. et al. (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol. 9: 1480-1486.
125. Miller, A. A., Stewart, C. F. & Tolley, E. A. (1990) Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother. Pharmacol. 25: 361-366.
126. Miller, A. A., Tolley, E. A., Niell, H. B. et al. Pharacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J. Clin. Oncol 11: 1179-1188.
127. Durand, R. E. & Goldie, J. H. (1987) Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat. Rep. 71: 673-679.
128. Schabel, F, Trader, M., Laster, W. et al. (1979) cis-Dichlorodiammineplatinum: Combination chemotherapy and cross-resistance studies with tumours in mice. Cancer Treat. Rep. 63: 1459-1473.
129. Tsai, C. M., Gazdar, A. F., Venzon, D. J. et al. (1989) Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res. 49: 2390-2397.
130. Eder, J., Teicher, B., Holden, S. et al. (1990) Ability of four potential topoisomerase II inhibitors to enhance the activity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin resistant subline. Cancer Chem. Pharmacol. 26: 423-428.
131. Kondo, H., Kanzawa, F., Nishio, K. et al. (1994) In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines. Jpn. J. Cancer Res. 85:1050-1056.
132. Bicknell, S. R., Plumb, J. A. & Kaye, S. B. (1991) Application of isobolograms to studies of modulation of cisplatin resistance. Br. J. Cancer 63.
133. Maksymiuk, A. W., Jett, J. R., Earle, J. D. et al. (1994) Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J. Clin. Oncol. 12: 70-76.
134. Relling, M. V, McLeod, H. L., Bowman, L. C. et al. (1994) Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin. Pharmacol. Ther. 56: 503-511.
135. Anzai, H., Frost, P. & Abbruzzese, J. L. (1992) Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33.
136. Kozelsky, T. K. & Bonner, J. A. (1995) Sequence dependent interaction of etoposide and topotecan. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36.
137. Kaufmann, S. H. (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 51: 1129-1136.
138. Branelle, D., Markovits, J. & Chouaib, S. (1990) Potentiation of TNF-mediated cell killing by VP-16: relationship to DNA single-strand break formation. Int. J. Cancer 46: 1048-1053.
139. Lestingi, T. M., Vokes, E. E., Mick, R. et al. (1994) A pharmacokinetic (PK) and pharmacodynamic (PD) study of etoposide (VP-16) combined with recombinant human interferon alfa-2b (rhlFNalpha-2b). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
140. Hand, A., Pelin, K., Halme M. et al. (1993) Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines. Anticancer Drugs 4: 365-368.
141. Von Hoff DD. (1991) In vitro data supporting interferon plus cytotoxic agent combinations. Semin Oncol 18: 58-61.
142. Usui, N., Pilaro, A. M., Matsushima, K. et al. (1992) Synergistic antitumor effects of combination treatment with human interleukin-1 alpha and etoposide. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33.
143. Monti, E., Mimnaugh, E. G. & Sinha, B. K. (1993) Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells. Biochim. Biophys Acta. 1180: 231-235.
144. Jia SF, McWatters, A., Kleinerman, E. S. (1994) Synergistic antitumor effect of VP-16 and IL-1, TNF alpha, or IFN gamma against human osteosarcoma cells. Proc. Annu. Meet Am. Assoc. Cancer Res. 35.
145. Kim, H. K., Zwelling, L. A., Sacks, P. E. et al. (1989) Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line. Cancer Res. 49: 1197-1201.
146. Timmer-Bosscha H, Guchelaar, H. J., de Vries, E. G. et al. (1992) Enhancement of etoposide (VP-16) cytotoxicity after all-trans retinoic acid induced cellular differentiation of murine embryonal carcinoma cells. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33.
147. Erba, E., Sen, S., Lorico, A. et al. (1992) Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. Eur. J. Cancer 28: 66-71.
148. Holden SA, Teicher, B. A., Robinson, M. F. et al. (1995) Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother. Pharmacol. 36: 165-171.
149. Lorico, A., Boiocchi, M., Rappa, G. et al. (1990) Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate. Int. J. Cancer 45: 156-162.
150. Joel, S., Clark, P., Slevin, M. (1995) Stability of the IV and oral formulations of etoposide in solution. Cancer Chemother. Pharmacol. 37: 117-124.
151. Schacter, L. P., Igwemezie, L. N., Seyedsadr, M. et al. (1994) Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother. Pharmacol. 34: S58-63.
152. Goss, G., Stewart, D. J., P, OD. et al. (1994) Comparative pharmacology of etoposide phosphate vs etoposide. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
153. Sessa, C., Zucchetti, M., Cerny, T. etal. (1995) Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J. Clin. Oncol. 13: 200-209.
154. Hainsworth, J. D., Levitan, N., Wampler, G. L. et al. (1995) Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. J. Clin. Oncol. 13: 1436-1442.
155. De Fusco, M. M. Dl., Gentili, D. et al. (1995) High-performance liquid Chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. J. Chromatogr. B. Biomed. Appl. 664: 409-414.
156. Ekimoto, H., Okamoto, K., Kusama, K. et al. (1992) Treatment-schedule dependency of antitumor effect of NK611, a novel water-soluble analog of etoposide, on human tumor xenografts. Proc. Annu. Meet. Am. Assoc. Cancer Res. 33.
157. Ekimoto, H., Okamoto K, Nakamori, K. et al. (1990) Antitumour and pharmacokinetic properties of a novel water-soluble analog (NK611). Proc. Am. Assoc. Cancer Res. 31: 449.
158. Long, B. H. & Casazza, A. M. (1994) Structure-activity relationships of VP-16 analogues. Cancer Chemother. Pharmacol. 34.
159. Anyanwutaku, I. O., Guo, X., Chen, H. X. et al. (1995) Activities of novel non glycosidic epipodophyllotoxins in etoposide-sensitive and resistant variants of human KB, P-388 cells and murine leukemia model (Meeting abstract). Proc. Annu. Meet. Am. Assoc. Cancer Res. 36.
160. Dombernofsky, P. & Nissen, N. (1973) Schedule dependency of the antileukaemic activity of ophyllotoxin-derivative VP16-213 in L1210 leukaemia. Acta Pathol Microbiol Scand [A] 81: 715-724.
161. Wolff, S. N., Grosh, W. W., Prater, K. et al. (1987) In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother. Pharmacol. 19: 246-249.
162. Matsushima, Y., Kanzawa, F., Hoshi, A. et al. (1985) Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother. Pharmacol. 14: 104-107.
163. Cavalli, F. (1982) VP16-213 (etoposide): a critical review of its activity. Cancer Chemother. Pharmacol 7.
164. Nissen, N. I., Dombernowsky, P., Hansen, H. H. et al. (1980) The epidodophyllotoxin derivatives VM26 and VP16-213, 1976-1979: A review. Recent Results Cancer Res 74: 98-106.
165. Radice, P. A., Bunn, P. A. J. & Ihde, D. C. (1979) Therapeutic trials with VP16 and VM26: Active agents in small cell lung cancer, non-Hodgkin's lymphoma and other malignancies. Cancer Treat. Rep. 63.
166. Rozencweig, M., van Hoff, D. D., Menney, J. E. et al. (1977) VM26 and VP16: A comparative analysis. Cancer 40.
167. Cavalli, F., Sonntag, R., Jungi, F. et al. (1978) VP16-213 monotherapy for remission induction of small cell lung cancer: A randomised trial using three dosage schedules. Cancer Treat. Rep. 62: 473-475.
168. Mead, G. M., Thompson, J., Sweetenham, J. W. et al. (1987) Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide. Cancer Chemother. Pharmacol. 19: 172-174.
169. Slevin, M. L., Clark, P. I., Joel, S. P. et al. (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 7: 1333-1340.
170. Clark, P. I., Slevin, M. L., Joel, S. P. et al. (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol. 12: 1427-1435.
171. Abratt, R. P., Willcox, P. A., deGroot, M. et al. (1991) Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur. J. Cancer 27: 28-30.
172. Hainsworth, J. D., Johnson, D. H., Frazier, S. R. et al. (1989) Chronic daily administration of oral etoposide - a phase I trial. J. Clin. Oncol. 7: 396-401.
173. Hainsworth, J. D. (1993) Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leuk. Lymphoma 10: 65-72.
174. Johnson, D. H., Greco, F. A., Strupp, J. et al. (1990) Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J. Clin. Oncol. 8: 1613-1617.
175. Clark, P. I. & Cottier, B. (1992) The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin. Oncol. 19: 36-39.
176. Sessa, C., Zucchetti M., Torri, V. et al. (1993) Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results. Ann. Oncol. 4: 553-558.
177. Slevin, M. L. & Joel, S. P. (1993) Prolonged oral etoposide in small cell lung cancer. Ann. Oncol. 4: 529-532.
178. Miller, A. A., Herndon, J. E., Hollis, D. R. et al. (1995) Schedule dependency of 21-day oral versus 3-day intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J. Clin. Oncol. 13: 1871-1879.
179. Joel, S. P., Dolega, O. E., Jones, K. et al. (1991) The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc. Annu. Meet. Am. Assoc. Cancer Res. 32: 178.
180. Hande, K. R., Krozely, M. G., Greco, F. A. et al. (1993) Bioavailability of low-dose oral etoposide. J. Clin. Oncol. 11: 374-377.
181. Harvey, V. J., Slevin, M. L., Joel, S. P. et al. (1985) Variable bioavailability following repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol. 21: 1315-1319.
182. Thompson, D. W., Hainsworth, J. D., Hande, K. R. et al. (1993) Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J. Clin. Oncol. 11: 1322-1328.
183. Kunitoh, H. & Watanabe, K. (1994) Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 12: 83-89.
184. Minami, H., Shimokata, K., Saka, H. et al. (1993) Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J. Clin. Oncol. 11: 1602-1608.
185. Minami, H., Ando, Y., Sakai, S. et al. (1995) Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J. Clin. Oncol. 13: 191-199.
186. Joel, S. P., Ellis, P., O'Byrne, K. et al. (1996) Therapeutic monitoring of continuous infusion etoposide in small cell lung cancer. J. Clin. Oncol. 14: 1903-1912.
187. Sarkar, M., Higa, G., Robbins, A. et al. (1994) Determination of the therapeutic window (TW) and a pharmacokinetic/pharmacodynamic (PK/PD) model for chronic low dose etoposide (E). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
188. Sonnichsen, D., Ribeiro, R., Luo, X. et al. (1995) Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in paediatric patients with solid tumours. Clin. Pharmacol. Ther. 58: 107.
189. Karlsson, M. O., Port, R. E. & Sheiner, L. B. (1995) A population model for the leukopenic effect of etoposide. Clin. Pharmacol. Therap. 57: 325-334.
190. Smith, P. J., Soues, S., Gottlieb, T. et al. (1994) Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br. J. Cancer 70: 914-921.
191. Recent advances in etoposide therapy. (Proceedings) (1991) Cancer 67: 215-329.
192. Novel approaches to the use of etoposide. (Proceedings) (1992) Semin. Oncol. 19: 1-63.
193. Current perspectives on the use of etoposide. (Proceedings) (1992) Semin. Oncol. 19: 1-83.
194. Belani, C. P., Doyle, L. A. & Aisner, J. (1994) Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol. 34.
195. Hainsworth, J. D. & Greco, F. A. (1995) Etoposide: twenty years later. Ann. Oncol. 6: 325-341.
196. Carney, D. N., Keane, M. & Grogan, L. (1992) Oral etoposide in small cell lung cancer. Semin. Oncol. 19: 40-44.
197. Smit, E. F., Carney, D. N., Harford, P. et al. (1989) A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44: 631-633.
198. Doward, A. J. (1991) A prospective study of low dose oral etoposide in poor prognosis small cell lung cancer (SCLC). Cancer Treat. Res. 7: 111.
199. Antman, K., Pomfret E., Karp, G. et al. (1984) Phase II trial of etoposide in previously treated small cell carcinoma of the lung. Cancer Treat. Rep. 68: 1413-1414.
200. Tucker, R., Ferguson, A. & Van Wyk C. (1978) Chemotherapy of small cell carcinoma of the lung with VP16-213. Cancer 41: 1710-1714.
201. Johnson, D. H., Hainsworth, J. D., Hande, K. R. et al. (1991) Current status of etoposide in the management of small cell lung cancer. Cancer 67: 231-244.
202. Hansen, M., Hirsch, F., Dombernowsky, P. et al. (1977) Treatment of small cell analplastic carcinoma of the lung with the oral solution of VP16-213. Cancer 40: 633-637.
203. Einhorn, L. H., Pennington, K. & McClean, J. (1990) Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin. Oncol. 17: 32-35.
204. Einhorn, L., Greco, F., Wampler, G. et al. (1987) Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin, vincristine in the treatment of small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 6: 168.
205. Hong, W. K., Nicaise, C., Lawson, R. et al. (1989) Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J. Clin. Oncol. 7: 450-456.
206. Abratt, R., Salton, D., Malan, J. et al. (1995) A prospective randomised study in limited disease small cell lung cancer: doxorubicin and vincristine plus either cyclophosphamide or etoposide. Eur. J. Cancer 31A: 1637-1639.
207. Jackson, D. V. Jr., Case, L. D., Zekan, P. J. et al. (1988) Improvement of long-term survival in extensive small cell lung cancer. J. Clin. Oncol. 6: 1161-1169.
208. Jett, J., Everson, L., Therneau, T. et al. (1990) Treatment of limited stage small cell lung cancer with cyclophosphamide, doxorubicin and vincristine with or without etoposide: A randomised trial of the North Central Cancer Treatment Group. J. Clin. Oncol. 8: 33-39.
209. Evans, W., Feld, R., Murray, N. et al. (1987) Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann. Intern. Med. 107: 451-458.
210. Fukuoka, M., Furuse, K., Saijo, N. et al. (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J. Natl. Cancer Inst. 83: 855-861.
211. Roth, B. J., Johnson, D. H., Einhorn, L. H. et al. (1992) Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase Iii trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 10: 282-291.
212. Feld, R., Evans, W, Coy, P. et al. (1987) Canadian multicenter randomised trial comparing sequential and alternating administrations of two non-cross resistant chemotherapy aions in patients with limited disease small cell lung cancer. J. Clin. Oncol. 5: 1401-1409.
213. Goodman, G., Crowley, J., Blasko, J. et al. (1990) Treatment of limited stage small cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus etoposide, vincristine, doxorubicin, cylophosphamide and chest radiotherapy. A Southwest Oncology Group Study. J. Clin. Oncol. 8: 39-47.
214. Einhorn, L., Crawford, J., Birch, R. et al. (1988) Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small cell lung cancer. J. Clin. Oncol. 6: 451-456.
215. Loehrer-P. J. Sr., Ansari-R., Gonin-R. et al. (1995) Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J. Clin. Oncol. 13: 2594-2599.
216. Smith, I. E. (1992) Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience. Semin. Oncol. 19: 24-27.
217. Strauss, G. M., Lynch, T. J., Elias, A. D. et al. (1995) A phase I study of ifosfamide/carboplatin/ etoposide/paclitaxel in advanced lung cancer. Semin. Oncol. 22: 70-74.
218. Bork, E., Ersboll, J., Dombernowsky, P. et al. (1991) Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J. Clin. Oncol. 9: 1627-1631.
219. Wolff, S. N., Birch, R., Sarma, P. et al. (1986) Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat. Rep. 70: 583-587.
220. Johnson, D., DeLeo, M., Hande, K. et al. (1987) High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive small cell lung cancer. J. Clin. Oncol. 5: 703-709.
221. Ihde, D. C., Mulshine, J. L., Kramer, B. S. et al. (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol. 12: 2022-2034.
222. Brugger, W., Frommhold, H., Pressler, K. et al. (1995) Use of high-dose etoposide/ifosfamide/ carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Semin. Oncol. 22: 3-8.
223. Woll, P. J., Hodgetts J., Lomax, L. et al. (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J. Clin. Oncol. 13: 652-659.
224. Ruckdeschel, J. C. (1991) Etoposide in the management of non-small cell lung cancer. Cancer 67: 250-253.
225. Waits, T. M., Johnson, D. H., Hainsworth, J. D. et al. (1992) Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J. Clin. Oncol. 10: 292-6.
226. Estape, J., Palombo, H., Sanchez-Lloret J. et al. (1992) Chronic oral etoposide in non-small cell lung carcinoma. Eur. J. Cancer 28A: 835-837.
227. Saxman, S., Loehrer, P. J. Sr., Logie, K. et al. (1991) Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Investig. New Drugs 9: 253-256.
228. Blumenreich, M. S., Sheth, S. P., Miller, C. L. et al. (1994) Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer. Am. J. Clin. Oncol. 17: 163-165.
229. Niederle, N., Ostermann, J., Achterrath, W. et al. (1991) Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study. Cancer Chemother. Pharmacol. 28: 59-62.
230. Rosso, R., Salvati F., Ardizzoni A. et al. (1990) Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force. Cancer 66: 130-141.
231. Robert, F., Wheeler, R. H., Molthrop, D. et al. (1994) Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 17: 383-386.
232. Miller, A. A., Niell, H. B. & Griffin, J. P. (1995) Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 12: 59-65.
233. Grunberg, S. M., Crowley, J., Livingston, R. et al. (1993) Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 11: 1598-1601.
234. Johnson, D. H., DeVore, R., Greco, F. A. et al. (1992) Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt Trial. Semin. Oncol. 19: 50-56.
235. Weick, J. K., Crowley, J., Natale, R. B. et al. (1991) A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 9: 1157-1162.
236. Tsougranis, A., Kalaitzidou E., Karapetsas, T. et al. (1992) Cisplatin-vindesine vs cisplatin-etoposide in advanced non-small cell lung cancer. Eighth Mediterranean Congress on Chemotherapy, May 1992.
237. Dhingra, H., Valdivieso, M., Carr, D. et al. (1985) Randomised trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small cell lung cancer. J. Clin. Oncol. 3: 176-183.
238. Muscato, J., Clamon, G., Perry, M. et al. (1991) Etoposide (VP-16) and Cisplatin (DDP) At Maximum Tolerated Dose (MTD) In Non-Small Cell Lung Carcinoma (Nsclc): a Calgb Study. Proc. Annu. Am. Soc. Clin. Oncol. 10.
239. Krigel, R. L., Palackdharry, C. S., Padavic, K. et al. (1994) Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. J. Clin. Oncol. 12: 1251-1258.
240. Newlands, E. & Bagshawe K. (1977) Epipodophyllotoxin derivative (VP16-213) in malignant teratomas and choriocarcinomas. Lancet 2: 87.
241. Hainsworth, J., William, S., Greco, F. et al. (1984) VP-16 in the treatment of refractory germinal neoplasms. In: Issell, B. F., Muggia, F. M. & Carter, S. K. eds Etoposide (VP-16): Current Status and New Developments. London: Academic Press, pp. 243-252.
242. Peckham, M. J., Barrett, A., Liew, K. H. et al. (1983) The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br. J. Cancer 47: 613-619.
243. Williams, S. D., Birch, R., Einhorn, L. H. et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316: 1435-1440.
244. Birch, R., Williams, S., Cone, A. et al. (1987) Prognostic factors for favourable outcome in disseminated germ cell tumours. J. Clin. Oncol. 4: 400-407.
245. Einhorn, L., Williams, S., Loehrer, P. et al. (1989) Evaluation of optimal duration of chemotherapy in favourable prognosis disseminated germ cell tumours: A Southeastern Cancer Study Group protocol. J. Clin. Oncol. 17: 387-391.
246. Nichols, C. R. (1992) The role of etoposide therapy in germ cell cancer. Semin. Oncol. 19: 72-77.
247. Loehrer, P. J. Sr., Johnson, D., Elson, P. et al. (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13: 470-476.
248. Kaye, S. B., Mead, G. M., Fossa, S. et al. (1995) An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
249. Fossa, S., Kaye, S. B., Mead, G. M. et al. (1995) An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing treatment with/without filgrastim (G-CSF). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
250. Nichols, C. R., Loehrer, P. J., Einhorn, L. H. et al. (1995) Phase III study of cisplatin, etoposide and bleomycin (PVP16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors; an intergroup trial. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
251. Stoter, G., Sleijfer, D. T., Schornagel, J. H. et al (1993) BEP vs VIP in intermediate risk patients (pts) with disseminated nonseminomatous testicular cancer (NSTC). Proc. Annu. Meet. Am. Soc. Oncol. 12.
252. de Wit R, Stoter, G., Sleijfer, D. T. et al. (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br. J. Cancer 71: 1311-1314.
253. Miller, J. C. & Einhorn, L. H. (1990) Phase II study of daily oral etoposide in refractory germ cell tumors. Semin. Oncol. 17 (Suppl. 2): 36-39.
254. Bokemeyer, C., Harstrick, A., Ruther, U. et al. (1995) Sequential treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell (PBSC) support in advanced germ cell cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
255. Bokemeyer, C., Schmoll, H. J., Arseniev, L. et al. (1994) Treatment of advanced testicular cancer with dose intensified chemotherapy plus GM-CSF alone or G-CSF and sequential harvesting and reinfusion of peripheral blood stem cells (PBSC). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
256. Nichols, C. R. (1994) Salvage treatment for germ cell tumors. First International Conference on Germ Cell Tumors, April 1994.
257. Lotz, J. P., Andre, T., Donsimoni, R. et al. (1995) High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 75: 874-885.
258. Siegert, W., Beyer, J., Strohscheer, I. et al. (1994) High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J. Clin. Oncol. 12: 1223-1231.
259. Rodenhuis, S., Vlasveld, L. T., Dubbelman, R. et al (1992) Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. Ann. Oncol. 3: 463-467.
260. O'Reilly, S., Klimo, P. & Connors, J. (1991) The evolving role of etoposide in the management of lymphomas and Hodgkins disease. Cancer 67: 271-280.
261. Jacobs, P., King, H. S., Dent, D. M. et al. (1985) VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma. Cancer 56: 1006-1013.
262. Hainsworth, J. D., Johnson, D. H., Frazier, S. R. et al. (1990) Chronic daily administration of oral etoposide in refractory lymphoma. Eur. J. Cancer 26: 818-821.
263. Fisher, R. I., Gaynor, E. R., Dahlberg, S. et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328: 1002-1006.
264. Fisher, R. I., Gaynor, E. R., Dahlberg, S. et al. (1994) A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann. Oncol. 2: 91-95.
265. Trumper, L, Renner, C. H., Nahler, M. et al. (1994) Dose intensification of CHOP by addition of etoposide and application in 14-day intervals: results of a Phase I/II study. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
266. Parker, B. A., Anderson, J. R., Canellos, G. P. et al. (1991) Dose Escalation Study Of CHOP Plus Etoposide (CHOPE) Without and With RHG-CSF In Untreated Non-Hodgkin's Lymphoma (NhI). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 10.
267. Wilson, WH, Bryant, G., Bates, S. et al. (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J. Clinn. Oncol. 11: 1573-1582.
268. Wilson, W. H., Chabner, B., Bryant, G. et al. (1995) A controlled trial of MDR-1 modulation with dex-verapamil (DV) in EPOCH-refractory lymphomas. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
269. Blume, K. G., Long, G. D., Negrin, R. S. et al. (1994) Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogenic bone marrow transplantation, Bone Marrow Transplant. 14: S9-10.
270. Bishop, J. F. (1991) Etoposide in the management of leukemia: a review. Semin. Oncol. 18: 62-69.
271. Bishop, J. F. (1992) Etoposide in the treatment of leukemias. Semin. Oncol. 19: 33-38.
272. Ho, A. D., Brado, B., Haas, R. et al. (1991) Etoposide in acute leukemia. Past experience and future perspectives. Cancer 67: 281-284.
273. Bandini, G., Baccarani, M., Cavazzini, G. et al. (1987) Treatment of acute non lymphocytic leukemia. Results of a prospective trial of daunorubicin, arabinosylcytosine and 6-thioguanine (DAT) versus DAT plus vindesine and etoposide. Haematologica 72: 431-7.
274. Bishop, J. F., Lowenthal, R. M., Joshua, D. et al. (1990) Etoposide in acute nonlymphocytic leukemia. A randomised trial from the Australian Leukemia Study Group. Blood 75: 27-32.
275. Bow, E. J., Gallant, G., Shore, T. et al. (1995) Non-cytarabine (ARA-C)-based induction therapy in adult acute myeloid leukemia (AML) with idarubicin (I), etoposide (E) and carboplatin (C) in Canada. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
276. Crooks, G. M. & Sato, J. K. (1995) Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology 17: 34-38.
277. Hilbe, W., Thaler, J., Eisterer, W. et al. (1994) Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Leuk. Res. 18: 655-658.
278. Daenen, S., Lowenberg, B., Sonneveld, P. et al. (1994) Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia 8: 6-10.
279. Bernstein, M. L., Whitehead, V. M., Devine, S. et al. (1993) Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study. Cancer 72: 1790-1794.
280. Friedenberg WR, Miller, H. J., Marx, J. J. Jr. et al. (1995) The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy. Am. J. Clin. Oncol. 18: 105-110.
281. Shephard, J. D., Reece, D. E., Barnett, M. J. et al. (1993) Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leuk. Lymphoma 9: 211-215.
282. Giralt, S. A., Le Maistre, C. F., Vriesendorp, H. M. et al. (1994) Etoposide, cyclophosphamide, total-body irradiation, and allogenic bone marrow transplantation for hematologic malignancies. J. Clin. Oncol. 12: 1923-1930.
283. Blume, K. G., Kopecky, K. J., Henslee-Downey, J. P. et al. (1993) A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 81. 2187-2193.
284. Kavanagh, J., Morris, M., Smalldone, L. et al (1989) A randomised trial of carboplatin versus continuous infusion etoposide in refractory epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 8: 163.
285. Kuhnle, H., Meerpohl, H., Lenaz, L. et al. (1988) Etoposide in cisplatin-refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. 7: 137.
286. Eckhardt, S., Hernadi Z, Thurzo, L et al. (1990) Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) study. Oncology 47: 289-295.
287. Hillcoat B. L., Campbell, J. J., Pepperell, R. et al. (1985) Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecologic Oncology 22: 162-166.
288. Hansen, F., Malthe, I. & Krog, H. (1990) Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. Gynecologic Oncology 36: 369-370.
289. Seymour, M. T., Mansi, J. L., Gallagher, C. J. et al. (1994) Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br. J. Cancer 69: 191-195.
290. de Wit, R., van der Burg, M. E., van den Gaast, A., et al. (1994) Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann. Oncol. 5: 656-657.
291. Kudelka, A., Edwards, C., Freedman, R. et al. (1994) A Phase II study of prolonged oral VP-16 in women with refractory epithelial ovarian carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
292. Hoskins P. J., Swenerton, K. D. (1994) Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12: 60-63.
293. Marzola, M., Zucchetti, M., Colombo, N. et al. (1993) Low-dose oral etoposide in epithelial cancer of the ovary. Ann. Oncol. 4: 517-519.
294. Markman, M., Hakes, T., Reichman, B. et al (1992) Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J. Cancer Res. Clin. Oncol. 119: 55-57.
295. Trimble, E. L., Adams, J. D., Vena, D. et al (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11: 2405-2410.
296. Nichols, C. R. (1992) Role of etoposide in treatment of breast cancer. Seminol. Oncol. 19: 67-71.
297. Wander, H. E., Rauschning, W, Meyer D. et al (1989) Phase II study with etoposide in previously untreated advanced breast cancer. Cancer Chemother. Pharmacol. 24: 261-263.
298. Bontenbal, M., Planting, A. S., Verweij, J. et al. (1995) Second-line chemotherapy with longterm low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res. Treat. 34: 185-189.
299. Martin, M., Lluch, A., Casado, A. et al (1994) Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J. Clin. Oncol. 12: 986-991.
300. Palombe, H., Estape, J., Vinolas, N. et al (1994) Chronic oral etoposide in advanced breast cancer. Cancer Chemother. Pharmacol. 33: 527-529.
301. Calvert, A. H., Lind, M. J., Millward, M. M. et al (1993) Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat. Rev. 19: 27-33.
302. Cerar, O., Cervek, J. & Cufer, T. (1992) Salvage chemotherapy with oral etoposide in metastatic breast cancer: preliminary report. Ann. Oncol. 3 .
303. Cocconi, G., Bisagni, G., Bacchi, M. et al (1991) Cisplatin and Etoposide As First-Line Chemotherapy For Metastatic Breast Carcinoma: a Prospective Randomized Trial Of the Italian Oncology Group For Clinical Research. J. Clin. Oncol. 9: 664-669.
304. Somlo, G., Doroshow, J. H., Forman, S. J. et al (1994) High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. Cancer 73: 1678-1685.
305. Yau, J., Butts, C., Huan, S. et al (1993) Dose intensification with high-dose cyclophosphamide, etoposide and cisplatin (HDCVP) without bone marrow or peripheral blood stem cell support: Ottawa Regional Cancer Centre experience. Proc. Annu. Meet Am. Assoc. Cancer Res. 34.
306. Bezwoda, W. R., Seymour, L. & Ariad, S. (1992) High-Dose Etoposide In Treatment Of Metastatic Breast Cancer. Oncology 49: 104-107.
307. Saez, R., Selby, G., Mandanas, R. et al. (1995) High-dose carboplatin, etoposide and cyclophosphamide: an active transplant regimen for breast cancer and germ cell tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
308. Macdonald J. S., Havlin, K. A. (1992) Etoposide in gastric cancer. Semin. Oncol. 19: 59-62.
309. Kelsen, D., Atiq, O. T., Salz, L et al. (1992) FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. 10: 541-548.
310. Icli, F, Karaoguz, H., Dinqol D. et al. (1993) Comparison of EAP and FAM combination chemotherapies in advanced gastric cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 12.
311. Haim, N., Tsalik, M. & Robinson, E. (1994) Treatment of gastric adenocarcinoma with the combination of etoposide, adriamycin and cisplatin (EAP): comparison between two schedules. Oncology 51: 102-107.
312. Wilke, H., Wils, J., Rougier, P. et al. (1995) Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer (GC). A trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internistische Onkologie). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14.
313. Ajani, J., Dumas, P., Pazdur, R. et al. (1993) Phase Il trial of oral etoposide in untreated patients with advanced gastric carcinoma. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 12.
314. Taal, B. G., Teller, F. G., ten Bokkel Huinink W. W. et al. (1994) Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann. Oncol. 5: 90-92.
315. Bjarnason, G. A., Cripps, C., Fine, S. et al. (1994) A Phase-I study of FLAME; 5-fluorouracil (5-FU), leucovorin (LV), doxorubicin (A), methotrexate (MTX), and oral etoposide (E), in patients with advanced gastric cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13.
316. Winick, N. J., McKenna, R. W., Shuster, J. J. et al. (1993) Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide. J. Clin. Oncol. 11: 209-217.
317. Chabot, G. G., de Forni, M., Bonnay, M. et al. (1994) Phase I study and bioavailability of oral etoposide phosphate (EP; BMY-40481) in cancer patients (Meeting abstract). Proc. Annu. Meet. Am. Assoc. Cancer Res. 35.